跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Cosmo Technologies Ltd.

首页临床试验发起方与机构Cosmo Technologies Ltd.

Cosmo Technologies Ltd.

ACTIVE

爱尔兰www.cosmo-restaurants.ieSubsidiary

隶属于 Cosmo Pharmaceuticals NV

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

49

29 进行中

药物批准

1

批准总数

监管机构

1

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

15

30.6%

3 期

9

18.4%

2 期

6

12.2%

早期 1 期

1

2.0%

不适用

1

2.0%

试验状态分布

进行中（未招募）

29

59.2%

已完成

19

38.8%

招募中

1

2.0%

相关临床试验

该机构主办的试验（49）

Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors

Jun 202290 名受试者

Colonic lesion staining and flagging efficacy of methylene blue in patients receiving a bowel cleansing preparation for colonoscopy

进行中（未招募）

Oct 2021100 名受试者

Study of efficacy and safety of Rifamycin SV-MMX¿ 600 mg tablets administered three or two times daily versus Placebo to patients with diarrhoea-predominant irritable bowel syndrome (IBS-D)

进行中（未招募）

Jan 2021342 名受试者

Investigation aimed to evaluate the blood levels and the safety of Methylene Blue MMX® 25 mg modified-release tablets administered to healthy volunteers receiving two different bowel cleaning preparation for colonoscopy

Sep 202024 名受试者

Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D

Dec 2017279 名受试者

Study of efficacy and safety of Rifamycin SV-MMX® 600 mg tablets administered three or two times daily versus Placebo to patients with diarrhoea-predominant irritable bowel syndrome (IBS-D)

进行中（未招募）

Jun 2017342 名受试者

Study of efficacy and safety of Rifamycin SV-MMX® 600 mg tablets administered three or two times daily versus Placebo to patients with diarrhoea-predominant irritable bowel syndrome (IBS-D)

进行中（未招募）

Jun 2017342 名受试者

Study of efficacy and safety of Rifamycin SV-MMX® 600 mg tablets administered three or two times daily versus Placebo to patients with diarrhoea-predominant irritable bowel syndrome (IBS-D)

进行中（未招募）

Jun 2017342 名受试者

第 1 页，共 7 页

药物批准

按机构分类的批准

EMA

European Medicines Agency

1

药物批准

近期批准

Lumeblue (previously known as Methylthioninium chloride Cosmo)

资讯

Lumeblue® First Prescriptions Issued in China for Colorectal Lesion Visualization

- China Medical System (CMS) announces the first prescriptions for Lumeblue® (methylthioninium chloride enteric-coated sustained-release tablets) have been issued in China. - Lumeblue® enhances visualization of colorectal lesions during colonoscopies, improving the detection rate of non-polypoid colorectal lesions and adenomas. - The oral diagnostic drug utilizes MMX™ technology for targeted delivery to the colon, simplifying the colonoscopy procedure and improving screening efficiency. - CMS obtained exclusive rights to Lumeblue® and is actively promoting its commercialization, marking the fifth innovative drug from CMS approved in China.

本页目录

概览
相关临床试验49
药物批准1
资讯1

返回机构列表